clinical trial · NCT06760364
A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
Advanced Pancreatic CancersCHT102
brief summary
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
started
Dec 25, 2024
primary completion
Dec 24, 2027
completion
Dec 24, 2039
last updated
Apr 10, 2025
detailed description
3 planned dose cohorts will be evaluated during dose escalation phase. The dose expansion will be initiated after SRC (safety review committee) review the avaliable safety, PK and preliminary efficacy data.
official title
A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol